Recursion Pharmaceuticals, Inc.
RXRX
$3.39
-$0.03-0.88%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -108.12M | -162.25M | -171.90M | -202.49M | -178.91M |
| Total Depreciation and Amortization | 19.48M | 21.04M | 23.85M | 19.33M | 12.95M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.89M | 50.15M | 36.48M | 57.05M | 53.23M |
| Change in Net Operating Assets | 10.68M | -26.30M | 35.15M | -5.85M | -2.71M |
| Cash from Operations | -46.07M | -117.36M | -76.42M | -131.96M | -115.43M |
| Capital Expenditure | -1.24M | -243.00K | -3.15M | -1.83M | -1.30M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 277.10M |
| Divestitures | 0.00 | 0.00 | 0.00 | -4.44M | -- |
| Other Investing Activities | 0.00 | -2.31M | -2.66M | -1.00M | -350.00K |
| Cash from Investing | -1.24M | -2.55M | -5.81M | -7.27M | 275.46M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.17M | -2.13M | -2.08M | -2.05M | -2.10M |
| Issuance of Common Stock | 134.17M | 253.47M | 102.74M | 42.57M | 12.74M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -3.00M | -- | -- |
| Cash from Financing | 132.01M | 251.34M | 97.66M | 40.53M | 10.64M |
| Foreign Exchange rate Adjustments | 2.09M | 1.87M | 9.26M | 4.83M | -3.47M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 86.78M | 133.30M | 24.69M | -93.87M | 167.19M |